澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

ACTINOGEN MEDICAL LTD

0.042

-0.001-2.33%

成交量：57.47万

成交额：2.42万

市值：1.45亿

市盈率：-8.50

高：0.044

开：0.044

低：0.042

收：0.043

52周最高：0.072

52周最低：0.019

股本：34.62亿

流通股本：26.08亿

量比：1.73

换手率：0.02%

股息：- -

股息率：- -

每股收益(TTM):-0.005

每股收益(LYR):-0.005

净资产收益率：-77.47%

总资产收益率：-41.91%

市净率：7.93

市盈率(LYR):-8.50

数据加载中...

总览公司新闻资讯公告

ACTINOGEN MEDICAL LTD的Xanamia关键性2B/3期阿尔茨海默试验完成247名参与者的随机分组并开始治疗

Actinogen：FDA同意仅需进行一项额外的关键试验，采用单一10毫克Xanamem剂量设计对比安慰剂的阿尔茨海默病试验

Actinogen Medical Ltd计划于2026年与欧洲药品管理局就阿尔茨海默病项目举行会议

Actinogen Medical Ltd与FDA达成协议，就Xanamem阿尔茨海默病药物未来美国上市审批所需的制造、临床及非临床活动事宜举行C类会议

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ACW.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ACW.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.042,"timestamp":1771977193845,"preClose":0.043,"halted":0,"volume":574731,"delay":0,"changeRate":-0.023255813953488233,"nameEN":"ACTINOGEN MEDICAL LTD","floatShares":2607880613,"shares":3461769000,"eps":-0.004944,"marketStatus":"交易中","change":-0.001,"latestTime":"02-25 10:55:03 AEDT","open":0.044,"high":0.044,"low":0.042,"amount":24182,"amplitude":0.046512,"askPrice":0.043,"askSize":753311,"bidPrice":0.042,"bidSize":1456870,"shortable":3,"etf":0,"ttmEps":-0.004944,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771995600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.043,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":1.731117,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2607880613,"roa":"-41.91%","roe":"-77.47%","lyrEps":-0.004944,"volumeRatio":1.731117,"shares":3461769000,"dividePrice":0,"high":0.044,"amplitude":0.046512,"preClose":0.043,"low":0.042,"week52Low":0.019,"pbRate":"7.93","psRate":"26.49","week52High":0.072,"institutionHeld":0,"latestPrice":0.042,"committee":0.318326,"eps":-0.004944,"divideRate":0,"volume":574731,"delay":0,"ttmEps":-0.004944,"open":0.044,"prevYearClose":0.061,"prevWeekClose":0.042,"prevMonthClose":0.045,"prevQuarterClose":0.061,"fiveDayClose":0.043,"twentyDayClose":0.045,"sixtyDayClose":0.061,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1153606662","title":"ACTINOGEN MEDICAL LTD的Xanamia关键性2B/3期阿尔茨海默试验完成247名参与者的随机分组并开始治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1153606662","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153606662?lang=zh_cn&edition=fundamental","pubTime":"2025-12-18 21:02","pubTimestamp":1766062944,"startTime":"0","endTime":"0","summary":"ACTINOGEN MEDICAL LTD的Xanamia关键性2B/3期阿尔茨海默试验完成247名参与者的随机分组并开始治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"1186330080","title":"Actinogen：FDA同意仅需进行一项额外的关键试验，采用单一10毫克Xanamem剂量设计对比安慰剂的阿尔茨海默病试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1186330080","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186330080?lang=zh_cn&edition=fundamental","pubTime":"2025-09-15 20:44","pubTimestamp":1757940254,"startTime":"0","endTime":"0","summary":"Actinogen：FDA同意仅需进行一项额外的关键试验，采用单一10毫克Xanamem剂量设计对比安慰剂的阿尔茨海默病试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","ACW.AU","BK7067"],"gpt_icon":0},{"id":"1164379463","title":"Actinogen Medical Ltd计划于2026年与欧洲药品管理局就阿尔茨海默病项目举行会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1164379463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164379463?lang=zh_cn&edition=fundamental","pubTime":"2025-09-15 20:42","pubTimestamp":1757940178,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd计划于2026年与欧洲药品管理局就阿尔茨海默病项目举行会议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"1157388737","title":"Actinogen Medical Ltd与FDA达成协议，就Xanamem阿尔茨海默病药物未来美国上市审批所需的制造、临床及非临床活动事宜举行C类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1157388737","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157388737?lang=zh_cn&edition=fundamental","pubTime":"2025-09-15 20:30","pubTimestamp":1757939416,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd与FDA在C类会议中就其阿尔茨海默病治疗药物Xanamem未来在美国市场获得批准所需的制造、临床和非临床活动达成了协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}